International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones

Conditions

Acute lymphoblastic leukemia

Brief summary

The primary endpoint, DFS, is defined as the time from randomization to first event (relapse, second malignancy, or death in complete remission) or time to last followup for patients without events, The primary endpoint, DFS, is defined as the time from randomization to first event (relapse, second malignancy, or death in complete remission) or time to last followup for patients without events, The primary endpoint, DFS, is defined as the time from randomization to first event (relapse, second malignancy, or death in complete remission) or time to last followup for patients without events, The primary endpoint, DFS, is defined as the time from randomization to first event (relapse, second malignancy, or death in complete remission) or time to last followup for patients without events

Related papers

No related papers found yet.

Interventions

DRUGTIOGUANINE

DRUGIMATINIB

DRUGDOXORUBICIN HYDROCHLORIDE

DRUGPEGASPARGASE

DRUGCYTARABINE

DRUGDEXAMETHASONE

DRUGDELTACORTENE 25 mg compresse

DRUGMERCAPTOPURINE

DRUGErwinase 10 000 U polvere per soluzione iniettabile/per infusione.

DRUGDAUNORUBICIN HYDROCHLORIDE

DRUGIFOSFAMIDE

DRUGMETHOTREXATE

DRUGCYCLOPHOSPHAMIDE

DRUGETOPOSIDE

DRUGVincristina Teva Italia 1 mg/ml soluzione iniettabile

DRUGDecortin H 5 mg töflur

DRUGHYDROCORTISONE SODIUM SUCCINATE

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
The primary endpoint, DFS, is defined as the time from randomization to first event (relapse, second malignancy, or death in complete remission) or time to last followup for patients without events, The primary endpoint, DFS, is defined as the time from randomization to first event (relapse, second malignancy, or death in complete remission) or time to last followup for patients without events, The primary endpoint, DFS, is defined as the time from randomization to first event (relapse, second malignancy, or death in complete remission) or time to last followup for patients without events, The primary endpoint, DFS, is defined as the time from randomization to first event (relapse, second malignancy, or death in complete remission) or time to last followup for patients without events	—

Measure

Time frame

The primary endpoint, DFS, is defined as the time from randomization to first event (relapse, second malignancy, or death in complete remission) or time to last followup for patients without events, The primary endpoint, DFS, is defined as the time from randomization to first event (relapse, second malignancy, or death in complete remission) or time to last followup for patients without events, The primary endpoint, DFS, is defined as the time from randomization to first event (relapse, second malignancy, or death in complete remission) or time to last followup for patients without events, The primary endpoint, DFS, is defined as the time from randomization to first event (relapse, second malignancy, or death in complete remission) or time to last followup for patients without events

—

Countries

Austria, Belgium, Czechia, Denmark, Finland, France, Germany, Italy, Netherlands, Poland, Spain, Sweden

Outcome results

None listed